Connect with us
Novo Nordisk says more than 246000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg’s … source
The US will let Novo Nordisk A/S sell it blockbuster weight loss drug Wegovy in a pill form. Millions of people already take the shot. A...
Novo Nordisk A/S won approval to sell a pill version of its obesity shot Wegovy in the US. Novo will start selling the pill, the first...
Novo Nordisk President and CEO Mike Doustdar says Christmas has come early with US approval of its Wegovy weight loss pill. source
Get a jump start on the US trading day with Matt Miller and Vonnie Quinn on “Bloomberg Open Interest.” A weight-loss game … source
US equity futures are holding their ground after a strong run as traders await some of the remaining data sets of 2025. Novo Nordisk won approval...
Novo Nordisk’s weight loss drugs Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years after Wegovy’s US launch, the Danish drugmaker’s...
A new study published in the Journal of the American College of Cardiology found that people taking Wegovy during the COVID … source
Dave Moore, senior vice president of U.S. operations at Novo Nordisk, says his company wants to “meet patients where they are.” ––– Subscribe to ABC News...
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored...
On this website we use first or third-party tools that store small files (cookie) on your device. Cookies are normally used to allow the site to run properly (technical cookies), to generate navigation usage reports (statistics cookies) and to suitable advertise our services/products (profiling cookies). We can directly use technical cookies, but you have the right to choose whether or not to enable statistical and profiling cookies. Enabling these cookies, you help us to offer you a better experience.